

DAFTAR PUSTAKA

Khawbung, J. L., Nath, D. & Chakraborty, S. Drug resistant Tuberculosis: A review. *Comp. Immunol. Microbiol. Infect. Dis.* **74**, 101574 (2021).

GLOBAL TB-SDG MONITORING FRAMEWORK.

Saleh, S. & Syahridha, S. FACTOR RELEATED OF ANTI-TUBERCULOSIS DRUG RESISTENCY ON PULMONARY TUBERCULOSIS PASIENT IN LABUANG BAJI HOSPITAL MAKASSAR. *Indones. J. Trop. Infect. Dis.* **7**, 40–44 (2018).

Alghamdi, S. *et al.* Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis. *Molecules* **25**, 5685 (2020).

Surya, A. *et al.* Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public–Private Collaboration. *J. Infect. Dis.* **216**, S724–S732 (2017).

Dashboard TB - TBC Indonesia. <https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/>.

Jameson, J. L. *Harrison's principles of internal medicine.* (McGraw-Hill Education, 2018).Indonesia, P. D. P. Tuberculosis: pedoman diagnosis dan penatalaksanaan di Indonesia. *Jakarta PDPI* 20–30 (2011).

Widyasrini, E. R., Probandari, A. N. & Reviono, R. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. *J. Epidemiol. Public Heal.* **2**, 45–57 (2017).

Sarwani SR, D. & Nurlaela, S. Faktor risiko multidrug resistant tuberculosis (MDR-TB). *KEMAS J. Kesehat. Masy.* **8**, 60–66 (2012).

Adenji, Knoll, Loots (2020). *Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.* 2020 Jul;104(13):5633-5662.doi: 10.1007/s00253-020-10606-y. Epub 2020 May 5.

Alghamdi,S, et al. (2020).*Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.* .Molecules 2020, 25, 5685; doi:10.3390/molecules25235685

Sarwani, Nurlaela, dkk (2012). *Factor risiko multidrug reistant tuberculosis (MDR-TB).*

vincent.(2019). *pola resistensi antibiotik pada kasus tb kambuh yang resisten di puskesmas kramat jati, jakarta timur pada tahun 2016-2018.*

Gracia, Osornio, et.all (2008) [Drug resistance of Mycobacterium tuberculosis in Orizaba, Veracruz. Implications for the tuberculosis prevention and control program.](#) *Rev Invest Clin.* 2008 Jul-Aug;53(4):315-23. PMID: 11599478 Spanish.

Becerra, Freeman, Bayona, et.all (2010). [Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.](#) *Int J Tuberc Lung Dis.* 2000 Feb;4(2):108-14. PMID: 10694087

Yee Hyung, Gee Young, et,all (2008). *Treatment of isoniazid-resistant pulmonary tuberculosis* [Treatment of isoniazid-resistant pulmonary tuberculosis.](#) *BMC Infect Dis.* 2008 Jan 23;8:6. doi: 10.1186/1471-2334-8-6. PMID: 18211720

Prasad, Verman, et.all (2011). Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients *Indian J Chest Dis Allied Sci.* 2006;48:183-6.

Chan-yeung, leung, et.all (2013) *Prevalence and predictors of default from tuberculosis treatment in Hongkong.* *Hongkong Med J.* 2003;9:263-8.

Mahmoudi A, Iseman MD (2016). *Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance.* *JAMA.* 1993;270:65-8.

Nugrahaeni, Malik. (2013). *ANALISIS PENYEBAB RESISTENSI OBAT ANTI TUBERKULOSIS* Dyan Kunthi Nugrahaeni*, Upep Saiful Malik. DOI <http://dx.doi.org/10.15294/kemas.v1i1.3341>

Khairani, Santoso, dkk (2009). *Role of Risk Factors in the Incidence of Multidrug-Resistant Tuberculosis* Alya Putri Khairani,1 Prayudi Santoso,2 Elsa Pudji Setiawati ISSN: 2302-1381; eISSN: 2338-4506; <http://doi.org/10.15850/ijhs.v5n2.991> IJIHS. 2017;5(2):57–63.

Paramasivan, Venkataraman, Chandrasekaran, et.all (2017). *Surveillance of drug resistance in tuberculosis in two districts of South India C. N. SUMMARY Tuberculosis Research Centre (Indian Council of Medical Research), Chetput, Chennai, India INT J TUBERC LUNG DIS* 6(6):479–484 © 2015 IUATLD

Tun-Chieh, Po-Liang Lu, Chun-Yu, et al. (2017). *Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis.* *International Society for Infectious*

Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1017/j.ijid.2017.11.0008

Marie, Saillour, robert, (2016). *Outcome of Multi-drug-resistant Tuberculosis in France A Nationwide Case-Control Study, National Reference Center for Surveillance of Mycobacterial Infections and Their Drug Resistance; and Service de Bactériologie-Hygiène, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.* AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 160.

Fan Wu, Jing Zhang, Fuhang Song, et.all (2016). *Chrysomycin A Derivatives for the Treatment of Multi-Drug Resistant Tuberculosis.* [ACS Central Science](#)

Anderson, S Tamne1 , J P Watson, et.all (2008) .*Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007.* <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2060>

Denis, Doreen, Claire, et.all (2019). *Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013–2017.* BMC Infectious Diseases (2019) 19:387 <https://doi.org/10.1186/s12879-019-4014-3>.

Jimmy, Duan-Rung dan Tzai-Hung (2008). *Delayed Treatment of Diagnosed Pulmonary Tuberculosis in Taiwan, 8:236 doi:10.1186/1471-2458-8-236* Received: 20 December 2007 Accepted: 13 July 2008 This article is available from: <http://www.biomedcentral.com/1471-2458/8/236>.